**Dr. Reddy’s Laboratories Q3 Results 2025**
On January 23, 2025, Dr. Reddy’s Laboratories announced its Q3 results, reporting a year-on-year revenue increase of 15.81%. The company’s profit rose by 2.38% year-on-year, amounting to ₹1,413.7 crore, while revenue reached ₹8,381.2 crore. Compared to the previous quarter, revenue grew by 4.27%, and profit saw a significant increase of 12.58%.
However, Selling, General, and Administrative expenses rose by 0.7% quarter-on-quarter and 16.53% year-on-year. The operating income for the quarter increased by 7.27% from the previous quarter and by 9.21% year-on-year. The Earnings Per Share (EPS) for Q3 was ₹16.94, reflecting a 1.68% year-on-year increase.
In terms of stock performance, Dr. Reddy’s Laboratories experienced a -1.02% return in the past week, a -5.93% return over the last six months, and a -7.14% year-to-date return. The company currently holds a market capitalization of ₹107,422.6 crore, with a 52-week high of ₹1,421.49 and a low of ₹1,120.
As of January 25, 2025, among 35 analysts covering the company, 5 have issued a Strong Sell rating, 8 a Sell rating, 9 a Hold rating, 7 a Buy rating, and 6 a Strong Buy rating. The consensus recommendation at this time is to Hold.
**Dr. Reddy’s Laboratories Financials**
| Period | Q3 (FY25) | Q2 (FY25) | Q-o-Q Growth | Q3 (FY24) | Y-o-Y Growth |
|———————–|———–|———–|————–|———–|————–|
| Total Revenue | 8381.2 | 8038.2 | +4.27% | 7236.8 | +15.81% |
| Selling/General/Admin Expenses | 3527.1 | 3502.6 | +0.7% | 3026.7 | +16.53% |
| Depreciation/Amortization | 471.4 | 397 | +18.74% | 373.5 | +26.21% |
| Total Operating Expense | 6579.6 | 6358.7 | +3.47% | 5587.2 | +17.76% |
| Operating Income | 1801.6 | 1679.5 | +7.27% | 1649.6 | +9.21% |
| Net Income Before Taxes | 1874.3 | 1917.4 | -2.25% | 1829.1 | +2.47% |
| Net Income | 1413.7 | 1255.7 | +12.58% | 1380.9 | +2.38% |
| Diluted Normalized EPS | 16.94 | 15.85 | +6.88% | 16.66 | +1.68% |
Stay informed on quarterly results with our results calendar.
